Drugs / REGN15505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07594106 | Jul 2026 → Oct 2030 expected | castration-resistant prostate carcinoma, clear cell renal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN15505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07594106 ↗ |